Overview

S Ketamine Use in Total Abdominal Hysterectomy

Status:
Withdrawn
Trial end date:
2015-06-01
Target enrollment:
0
Participant gender:
Female
Summary
This study investigates the effect of low dose S+ketamine compared to placebo on cumulative morphine consumption at 24 hours in women undergoing open abdominal hysterectomy with remifentanil-propofol target controlled infusion. It compares the adverse effect profile in patients receiving S+ketamine as compared to those who did not. Participants are randomly distributed in two groups of 45 patient's each.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
KK Women's and Children's Hospital
Treatments:
Esketamine
Ketamine
Morphine
Criteria
Inclusion Criteria:

- Females above the age of 21 years old scheduled undergoing open abdominal hysterectomy
with remifentanil-propofol TCI in KKH for benign condition (fibroids, adenomyosis),

- Be willing and able to give written informed consent for participation in this study

- ASA I/II patient's.

Exclusion Criteria:

- Patient with contraindications to the use of S+ketamine, as listed in the product
label e.g. untreated or insufficiently treated thyroid hyperfunction, unstable angina
pectoris or myocardial infarction within the last 6 months, diseases of the CNS,
increased intraocular pressure and perforating ocular injuries, surgical procedures in
the upper respiratory tract, etc

- Patients with a h/o drug or alcohol abuse

- Regular use of analgesics, or use of opioids within 12 hours of surgery

- Patient on chronic use of benzodiazepine or neurololeptics

- Patient on thyroid replacement hormone

- H/o IHD,HTN,Thyroid disorder.

- BMI> 30kg/m2.

- H/o Psychiatric disorder.

- Laproscopic surgery converted to open surgery.

- Pregnant or breast feeding female's.